Analysis-Can nicotine pouches drive Big Tobacco’s future beyond cigarettes?

Big Tobacco’s fastest growth bet—nicotine pouches (e.g., Zyn, Velo)—is expanding volumes 27.5% to ~700 million pouches in 1H 2026, with BAT projecting UK/industry pouch revenue to rise from £4B in 2025 to £11B by 2030 (industry users ~47M). However, WHO and regulators are tightening scrutiny over youth uptake and marketing, with some countries still lacking specific rules (160 as of May) and additional EU/UK restrictions likely to weigh on growth. The stock tape ends lower as oil rises, while investors look ahead to Fed minutes and retail earnings this week.

Analysis

The market is likely overpricing the strategic optionality and underpricing the adoption curve risk. Pouches are attractive because they are a high-margin mix item, but that value only accrues if the category scales beyond a niche set of nicotine users; otherwise the lift to consolidated earnings is too small to justify a durable multiple rerate. For PM, the best-case is not just volume growth but mix shift away from lower-quality combustible cash flows, which can support margin and free cash flow even if topline growth stays modest.

Relative positioning matters more than the absolute story. PM has the cleaner proof point in a market where oral nicotine is already normalized, while BTI’s upside depends on convincing consumers in less-established markets and navigating a more fragmented regulatory environment. That makes BTI more levered to policy headlines and less predictable on a 1-3 month horizon, even though it may screen cheaper on standard multiples.

The contrarian risk is that investors extrapolate Sweden/U.S. behavior into geographies where oral nicotine never becomes a mass habit. If adoption stalls, the category remains a valuation narrative rather than an earnings engine, and the stocks can de-rate once the next quarter shows slower pouch mix or higher marketing spend. Over 6-18 months, tighter rules on strength, packaging, and sampling are the key falsifier; any sign that regulators are moving faster than user adoption would cap the rerating.

Key Decisions for Investors

• Long PM / short BTI for 1-3 months into the next earnings cycle: PM has the more proven pouch monetization path, while BTI carries higher execution and EU/UK regulatory risk. Target a 5-8% relative move; cut the pair if BTI prints materially faster pouch revenue growth without incremental compliance drag.
• Add PM on pullbacks rather than chasing strength: the category is still too small to drive a near-term EPS step-change, so entry is better on any 3-5% selloff tied to broader tobacco weakness.
• Avoid BTI outright long until there is clearer evidence that ex-US pouch adoption can sustain without a regulatory reset; use it only as a trading vehicle around specific pouch-volume updates or policy headlines.
• Watch MO as a secondary short if U.S. pouch share keeps moving away from combustion: pouches can pressure the domestic nicotine franchise faster than consensus expects, but this is a lower-conviction expression until we see next-quarter share data.
• Set a watch level on regulatory headlines from the UK/EU: if plain-packaging or strength restrictions broaden, reassess BTI exposure immediately, as that would likely compress the category’s terminal-margin assumption.